

September 1, 2016



## **VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET**

NAMUR, Belgium, Sept. 1, 2016 /PRNewswire/-- [VolitionRx Limited](#) (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced it will host a conference call on Tuesday, September 6, 2016, at 8:30 a.m. U.S. Eastern Time, to update the market on its commercialization strategy.

Cameron Reynolds, Chief Executive Officer of VolitionRx, will host the call and provide an update on recent developments relating to its NuQ® blood-based diagnostic platform and corporate branding.

<b>Event:</b>	VolitionRx Product Launch Update Conference Call
<b>Date:</b>	Tuesday, September 6, 2016
<b>Time:</b>	8:30 AM (Eastern Time)
<b>U.S. &amp; Canada (Toll-free) Dial-in:</b>	1-888-318-7456
<b>International (Toll) Dial-in:</b>	1-719-325-2388
<b>Conference ID:</b>	3832516

An audio webcast of the conference call will be accessible live and archived on the investor relations page of VolitionRx's website, <http://ir.volitionrx.com/>, for one year.

A telephone replay of the call will be available until September 20, 2016. To access the replay, dial 1-877-870-5176 (U.S. and Canada) or 1-858-384-5517 (international) and use the replay pin number 3832516.

### **About VolitionRx**

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (<http://www.volitionrx.com>) or connect with us via [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

## Media / Investor Contacts

Louise Day, VolitionRx  
[L.Day@volitionrx.com](mailto:L.Day@volitionrx.com)  
+44 (0)7557 774 620

Scott Powell, VolitionRx  
[S.Powell@volitionrx.com](mailto:S.Powell@volitionrx.com)  
+1 (646) 650-1351

Tirth Patel, Edison Advisors  
[tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)  
+1 (646) 653-7035

Katherine Fennell, Edison Advisors  
[kfennell@edisongroup.com](mailto:kfennell@edisongroup.com)  
+44 (0) 20 7841 1556

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-schedules-product-launch-update-conference-call-for-tuesday-september-6-2016-at-830-am-et-300320003.html>

SOURCE VolitionRx Ltd